Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers
暂无分享,去创建一个
W. Sluiter | T. Links | R. Dullaart | M. Kerstens | M. D. de Jong | K. Eijkelenkamp | Thamara E. Osinga | A. V. D. van der Horst-Schrivers
[1] Robert A. Smith,et al. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. , 2016, Critical reviews in oncology/hematology.
[2] C. Tops,et al. Phenotype of SDHB mutation carriers in the Netherlands , 2014, Familial Cancer.
[3] J. Adler,et al. Current approaches and recent developments in the management of head and neck paragangliomas. , 2014, Endocrine reviews.
[4] E. D. de Vries,et al. Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. , 2013, Endocrine-related cancer.
[5] O. Dekkers,et al. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis , 2012, Journal of Medical Genetics.
[6] H. Brenner,et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. , 2012, Gastroenterology.
[7] H. Neumann,et al. Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma , 2012, Hormones and Cancer.
[8] K. Nathanson,et al. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. , 2012, Cancer genetics.
[9] A. Knudson,et al. A continuum model for tumour suppression , 2011, Nature.
[10] R. Milne,et al. Are we overestimating the penetrance of mutations in SDHB? , 2010, Human mutation.
[11] Fiona Douglas,et al. Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.
[12] C. Eng,et al. The approach to the patient with paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.
[13] A. Vénisse,et al. Penetrance and clinical consequences of a gross SDHB deletion in a large family , 2009, Clinical genetics.
[14] D. Berney,et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH‐B) gene mutation carriers , 2008, Clinical endocrinology.
[15] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[16] E. D. de Vries,et al. Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. , 2007, Clinical chemistry.
[17] K. Byth,et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.
[18] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[19] A. Knudson,et al. Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.
[20] E S Husebye,et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.
[21] A. V. D. van der Mey,et al. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal , 2000, Cancer.